Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts

Blood, Vol. 110, Issue 5, 1516-1518, September 1, 2007
This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome
Blood Józsi et al. 110: 1516

Supplemental materials for: Jozsi et al, Vol 110, Issue 5, 1516-1518

Files in this Data Supplement:

  • Figure S1. Identification of autoantibody positive patients (JPG, 62.3 KB) -
    (A) Plasma samples of aHUS (n = 51) and D+ HUS (n = 9) patients as well as healthy donors (n = 30) were analyzed for binding on immobilized purified FH in an ELISA assay. The samples having an OD value above the mean plus 2 SD of those in the control group were considered positive. (B) Dose-dependent binding of the autoantibody-positive plasma samples of 5 aHUS patients to immobilized FH, indicating different autoantibody titers. (C) Adsorption of IgG from the patients’ plasma by incubation with Protein G beads removed FH autoreactivity. (D) Isotypes of FH-specific IgG in the plasma samples were determined using mouse antibodies specific to human IgG1, IgG2, IgG3, and IgG4.





  • Figure S2. Competition assays show C-terminal specificity for autoantibody binding (JPG, 81.8 KB) -
    C-terminally binding mAbs (C02, C14, and C18; dotted lines), but not mAbs binding outside SCR19-20 (continuous lines), exhibited dose-dependent inhibitory activity on autoantibody binding to FH as shown for plasma of (A) patient no. 564 and (B) patient no. 520. (C) The FH SCR15-20 fragment (dotted lines), but not the SCR15-18 fragment (continuous lines), inhibited autoantibody binding to FH in a dose-dependent manner as shown for three patients.





  • Figure S3. Characterization of the IgG fraction purified from patient’s plasma (JPG, 31.5 KB) -
    (A) Purified IgG of patient no. 564 bound specifically to the FH fragments SCR15-20 and SCR19-20 (ie, those containing the most C-terminal domains; filled bars). Control IgG purified from a healthy donor showed no specific binding (open bars). (B) Dose-dependent binding of purified IgG from patients no. 422, no. 520, and no. 564 to immobilized FH.





This Article
Right arrow Abstract
Right arrow Full Text
Services
Right arrow Email this article to a friend
Right arrow Alert me to new issues of the journal
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020